Plant Form Header
PlantForm voted "Most Promising Technology"

PlantForm Corporation received the “Most Promising Technology” award at the 2012 Venture Forum in Buffalo, New York, May 16-17.

PlantForm was one of 33 companies from a wide range of industries selected to present at the forum, a partnership between Buffalo Niagara's annual Bright Forum and the Center for Economic Growth's annual SmartStart UNYTECH Forum.

"We’re pleased to receive this award, which recognizes our technology’s potential to dramatically reduce the cost of life-saving antibody drugs," said President and CEO Dr. Don Stewart. "We are currently raising Series A capital to advance PlantForm into the regulatory approval process for our biosimilar version of the breast cancer drug Herceptin®."

"This venture forum provided an excellent opportunity to attract interest in our company and assist us in raising the necessary capital required to move the company forward. We are seeking the right partner to finance our biosimilar product opportunities and realize value for our current investors."

PlantForm also recently presented at BioPartnering North America in Vancouver, Bio-Europe Spring 2012 in Amsterdam, and SPI 2012 in West Palm Beach, Florida. PlantForm will attend the BIO International Convention in Boston June 18-22.

Antibody pipeline advances
PlantForm’s HIV/AIDS antibody project is under way: various production approaches have been evaluated in the lab, a preferred system has been identified, and product development has begun.

Earlier this year, the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) awarded the company $292,777 to develop antibodies for the treatment of HIV.

Funding for the project comes from NRC-IRAP's Canadian HIV Technology Development (CHTD) Program, part of the Canadian HIV Vaccine Initiative, a collaborative effort between the Government of Canada and the Bill & Melinda Gates Foundation.

"Expression of the HIV/AIDS antibody, as well as the recent demonstration of high-level expression of our second biosimilar drug candidate, a biosimilar Avastin®, confirms the wide utility of PlantForm’s expression platform," Dr. Stewart said. Avastin® (bevacizumab), which is used to treat colon cancer, has global sales of $8.9 billion.

Join us online!
Get regular updates on our activities and industry news by following PlantForm on Twitter and LinkedIn:
Summer 2012

Senate invites PlantForm input

Chief Scientific Officer Dr. Chris Hall appeared before the Senate Standing Committee on Agriculture and Forestry May 31 to provide information about using plants to manufacture pharmaceuticals.

Dr. Hall outlined PlantForm’s progress to date in bringing biosimilar trastuzumab to market and developing additional antibody drug candidates.

The market for biosimilar drugs is “virtually untapped,” he told the committee. “About $100 billion in biologics lose patent protection from now till 2020, so there is a huge opportunity for us to come in and make biosimilar drugs… PlantForm's technology platform will substantially reduce the cost of goods to enter this marketplace.”

Dr. Hall noted that, while there is good support in Canada for early-stage research by companies, more could be done by governments and the private sector to help companies bridge the funding gap that many face during the product development and testing required to advance to commercialization.

Media coverage
PlantForm has received significant media attention over the last few months, including coverage on the front page of The Globe and Mail (click to read), as well as in the Guelph Mercury and the Buffalo News.

Our tobacco plant manufacturing platform was also featured in a Government of Ontario video, The Science of Life.

Upcoming Events
June 18-21
2012 BIO International Convention, Boston

PlantForm is a Canadian company focused on providing
low-cost therapeutic antibody drugs that fight cancer and other critical illnesses.

Our mailing address is:
1920 Yonge St, Suite 200
Toronto, Ontario
For more information, contact:
Don Stewart
President & CEO